2005
DOI: 10.1200/jco.2005.13.011
|View full text |Cite
|
Sign up to set email alerts
|

Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer

Abstract: L-BLP25 maintenance therapy in patients with advanced NSCLC is feasible with minimal toxicity. The survival difference of 4.4 months observed with the vaccine did not reach statistical significance. In the subgroup of patients with stage IIIB LR disease, a strong trend in 2-year survival in favor of L-BLP25 was observed.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
250
0
4

Year Published

2008
2008
2019
2019

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 373 publications
(258 citation statements)
references
References 25 publications
4
250
0
4
Order By: Relevance
“…These include peptide vaccines prepared from single [3] or multiple [24] peptides derived from NSCLC cells, as well as DC pulsed with peptides derived from NSCLC cells [13]. The glycoprotein MUC-1 [7] and epidermal growth factor [33], both of which are found on many tumor cells including NSCLC cells, have also been tested as therapeutic vaccines. These vaccines did not cause significant side-effects; however, their therapeutic efficacy remains to be determined.…”
Section: Discussionmentioning
confidence: 99%
“…These include peptide vaccines prepared from single [3] or multiple [24] peptides derived from NSCLC cells, as well as DC pulsed with peptides derived from NSCLC cells [13]. The glycoprotein MUC-1 [7] and epidermal growth factor [33], both of which are found on many tumor cells including NSCLC cells, have also been tested as therapeutic vaccines. These vaccines did not cause significant side-effects; however, their therapeutic efficacy remains to be determined.…”
Section: Discussionmentioning
confidence: 99%
“…The BLP25 liposome vaccine [L-BLP25 (Stimuvax: Oncothyreon, Seattle, WA, U.S.A.)] targets the exposed core peptide of the muc1 (cell surface-associated mucin 1) tumour-associated antigen 21 . The vaccine is designed to induce a cellular immune response figure 1 Tumour growth, a dynamic that may lead to immune rejection of tumour tissues that express the m uc1 antigen.…”
Section: Data From Non-prostate Cancer Immunotherapy Clinical Trialsmentioning
confidence: 99%
“…The vaccine is designed to induce a cellular immune response figure 1 Tumour growth, a dynamic that may lead to immune rejection of tumour tissues that express the m uc1 antigen. A randomized phase iib trial of L-BLP25 in patients with stage iiibiv non-small-cell lung cancer after stable disease or response to primary chemotherapy has been completed 21 . The vaccination arm included 88 patients, and the best supportive care (bsc) arm, 83.…”
Section: Data From Non-prostate Cancer Immunotherapy Clinical Trialsmentioning
confidence: 99%
“…Early efforts to develop MUC1-based cancer vaccines focused on the use of unglycosylated MUC1 tandem repeat peptides of different lengths, conjugated to different carriers and/or administered with an adjuvant (8,(20)(21)(22)(23)(24)(25)(26)(27). In general, these strategies have failed to elicit effective immune responses to MUC1-expressing cancer cells, probably due to the conformational disparities between nonglycosylated vaccine sequences and tumor-expressed, aberrantly glycosylated MUC1 (10)(11)(12).…”
mentioning
confidence: 99%